Profile for European Patent Office Patent: 3052628
✉ Email this page to a colleague
| Country | SPC | SPC Expiration |
|---|---|---|
| Netherlands | 301061 | ⤷ Start Trial |
| Luxembourg | LUC00175 | ⤷ Start Trial |
| Germany | 122020000045 | ⤷ Start Trial |
| Lithuania | PA2020527 | ⤷ Start Trial |
| Belgium | 2020C/532 | ⤷ Start Trial |
| Denmark | CA 2020 00042 | ⤷ Start Trial |
US Patent Family Members and Approved Drugs for European Patent Office Patent: 3052628
| US Patent Number | US Expiration Date | US Applicant | US Tradename | Generic Name |
|---|---|---|---|---|
| 10,119,143 | Oct 3, 2034 | Alnylam Pharms Inc | GIVLAARI | givosiran sodium |
| 11,028,392 | Oct 3, 2034 | Alnylam Pharms Inc | GIVLAARI | givosiran sodium |
| >US Patent Number | >US Expiration Date | >US Applicant | >US Tradename | >Generic Name |
